Cargando…
Timing is everything: Clinical evidence supports pre-symptomatic treatment for spinal muscular atrophy
Two new studies by Strauss et al. demonstrated safe and effective pre-symptomatic delivery of gene therapy in children with spinal muscular atrophy (SMA).(1)(,)(2) These results highlight the importance of newborn screening programs and early therapy delivery for SMA.
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418840/ https://www.ncbi.nlm.nih.gov/pubmed/35977471 http://dx.doi.org/10.1016/j.xcrm.2022.100725 |